Fast forward: fibroid management in 2042

Looking into the Crystal Ball

Like Comment
Related Content

VOLUME 2, ISSUE 2, P114-115, MAY 01, 2021


Malak El Sabeh, M.D., Mostafa A. Borahay, M.D., Ph.D., M.B.A. 


It is January 5, 2042. I did not have surgeries this week, only office visits, teaching, and research. The first patient scheduled in the clinic today was a 42-year-old lady with a body mass index of 34 kg/m2 and a history of hypertension. She initially presented for heavy periods and pelvic pain. Imaging revealed several small fibroids, and her laboratory results showed elevated cholesterol and triglycerides. Her fibroid biomarkers suggested that her metabolic disorders were contributing to the development of her fibroids. I discussed the findings with her, recommended lifestyle changes, and started her on simvastatin. I also started her on an angiotensin-converting enzyme (ACE) inhibitor for her elevated blood pressure.

Read the full text here. 

Fertility and Sterility

Editorial Office, American Society for Reproductive Medicine

Fertility and Sterility® is an international journal for obstetricians, gynecologists, reproductive endocrinologists, urologists, basic scientists and others who treat and investigate problems of infertility and human reproductive disorders.